Select Language:
Weight-loss medications like semaglutide and tirzepatide have gained significant attention in recent years.Originally designed to control blood sugar levels in people with diabetes, these drugs are now commonly used for weight management as obesity becomes an increasing global health concern. Millions worldwide have turned to these medications, and a new large-scale study suggests they might do more than just aid weight loss—they could potentially lower the risk of certain cancers associated with obesity.
Published in the journal Annals of Oncology, the research analyzed data from over 229,000 adults in the United States who were obese but did not have diabetes. This makes it the first extensive study to specifically explore how these medications impact cancer risk among non-diabetic individuals seeking weight loss.
Obesity is a major health issue that elevates the risk of cardiovascular diseases, stroke, type 2 diabetes, and numerous types of cancer. Scientists identify at least 13 cancers strongly linked to excess weight, including those of the uterus, breast, colon, kidney, pancreas, thyroid, liver, gallbladder, ovary, stomach, and esophagus, alongside certain blood and brain cancers. These obesity-related cancers account for a substantial portion of cancer cases in affluent nations, with rates climbing among younger populations.
Researchers from Houston Methodist Hospital set out to determine whether GLP-1 receptor agonists—such as semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound)—could impact this risk. They examined records from a healthcare database covering more than 113 million patients, identifying 229,467 obese adults without diabetes. Of these, around 86,000 had been prescribed GLP-1 medications, while roughly 143,000 had only received diet and exercise advice.
The average age of participants was 47. The researchers carefully matched patients in the two groups to ensure fair comparisons, resulting in nearly 81,000 individuals in each group.
Over an average follow-up of two years, those taking GLP-1 drugs experienced a 41% reduction in the risk of developing obesity-related cancers compared to those relying on lifestyle changes alone. The greatest drop was seen among men, with a nearly 70% decrease in cancer risk, and a 58% reduction in endometrial (uterine) cancer, which strongly correlates with obesity.
The study also revealed differences in outcomes among racial groups. White patients experienced about a 50% reduction in cancer risk, whereas similar benefits were not observed in Black patients. The researchers suggest this disparity could stem from factors like healthcare access, underlying health conditions, social determinants, or biological differences, warranting further investigation.
Among the medications studied, tirzepatide showed the most significant reduction in cancer risk, though all GLP-1 drugs appeared to offer protective benefits. Dr. Aparna Kamat, a gynecologic cancer specialist and the study’s senior author, noted that these findings might indicate that such medications have effects extending beyond weight management.
Previous research hinted that diabetic patients taking these drugs had lower cancer risks, but this study is groundbreaking in examining their impact on younger, non-diabetic users—who now constitute most of the medication’s user base.
Several mechanisms could explain these results. Weight loss can decrease inflammation, modify hormones linked to obesity, improve metabolism, and reduce biological processes that promote cancer growth. However, it remains unclear whether the drugs directly inhibit cancer development or if the benefits mainly result from weight reduction.
The authors caution that the study is observational, relying on existing medical records, which means it cannot establish cause-and-effect relationships. The relatively short follow-up period—around two years—also limits findings, as cancer development typically takes many years. Longer-term studies are necessary to confirm whether these protective effects persist over time.
Despite these limitations, the findings are promising. Obesity-related cancers are becoming increasingly prevalent, and if future clinical trials validate these results, weight-loss medications might play a vital role not just in managing obesity but also in reducing cancer risk.
Overall, the study offers compelling evidence that GLP-1 therapies may deliver health benefits beyond weight loss. The large sample size adds confidence, but it remains essential to conduct extended research before drawing definitive conclusions. For now, these drugs should continue to be prescribed based on approved medical indications. Still, these findings might eventually influence discussions about cancer prevention when healthcare providers and patients consider treatment options.
For those interested in cancer prevention, current studies suggest that a low-carb diet could raise overall cancer risk, while vitamin D supplementation might significantly reduce cancer mortality.
Additional research has examined how dietary choices, such as dairy consumption, influence health. Recent findings show drinking milk may impact heart disease and cancer risks, and higher intake of dairy foods has been linked to an increased risk of prostate cancer.
Source: Houston Methodist Hospital.
ChatGPT
Perplexity
Gemini AI
Grok AI
